Contact
info@topadur.com+41 44 755 44 66Topadur Pharma AG | Grabenstrasse 11a, 8952 Schlieren, Switzerland
The Board of Directors of Topadur Pharma AG announces that Pascal Brenneisen will leave his position as CEO to pursue new professional challenges.
Since taking on the role in 2023, Mr. Brenneisen has made significant progress in guiding the company toward a future-oriented strategy and fostering a cultural change in preparation for an IPO. The Board of Directors expresses its appreciation to Mr. Brenneisen for his dedication to the company.
His vision has laid a good foundation for the company’s growth and success. As active shareholder he will still stay connected to Topadur Pharma AG.
Chairman of the Board, Dr. Reto Naef, will take over direct corporate leadership of the company on an interim basis until a successor is appointed.
The Board wishes Mr. Brenneisen all the best for his future.
A Dual-Acting Nitric Oxide Donor and Phosphodiesterase 5 Inhibitor Activates Autophagy in Primary Skin Fibroblasts.
Read moreCHF 1.76 million is awarded from Innosuisse for the Phase 2a clinical trial with TOP-N53 in the treatment of digital ulcers
Read moreTOPADUR announced that Pascal Brenneisen has been appointed CEO, effective April 1, 2023, on top of his Board member assignment.
Read more
